Back to News
Market Impact: 0.15
Nitto Avecia Achieves Third Consecutive FDA Inspection with No Action Indicated
Source: Business Wire
Regulation & LegislationHealthcare & BiotechCompany Fundamentals
Nitto Avecia reported a third consecutive FDA inspection resulting in a No Action Indicated (NAI) classification, this time at its Milford, Massachusetts facility. The brief report provides no further inspection details or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Australia top court rules against coal mine expansion, citing climate harm
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- GIC Private Ltd, Medline 10% owner, sells over $721m in shares
- Paramount's hard-fought takeover of Warner Bros. Discovery closes Tuesday. Here's how we got here
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes